10th Edition of
World Congress on Infectious Diseases & One Health
October 05-07, 2026 | Tokyo, Japan
Antifungals represent a critical class of medications designed to combat fungal infections, offering relief from ailments caused by a diverse array of fungi. Azoles, such as fluconazole, interfere with fungal cell membrane synthesis, disrupting their structural integrity and impeding growth. Polyenes, like amphotericin B, bind to fungal cell membranes, causing membrane leakage and eventual cell death. Echinocandins, a newer class, inhibit the synthesis of fungal cell walls, curbing the progression of invasive fungal infections. Antifungals find applications in treating common conditions like athlete's foot and yeast infections, as well as more severe systemic infections such as candidiasis and aspergillosis. However, challenges persist, including the emergence of antifungal resistance, particularly in immunocompromised individuals. Ongoing research strives to unravel new antifungal targets and develop innovative strategies to address the dynamic landscape of fungal infections.
Title : Molecular crosstalk between the host and pathogen in Streptococcus pyogenes virulence
Francis J Castellino, University of Notre Dame, United States
Title : Phenotypic characterisation of non tuberculous mycobacterium species isolated from clinical specimens
Anant Marathe, Parul Institute of Medical Sciences and Research, Parul University, India
Title : An unprecedented West Nile virus outbreak in Israel (2024): A textbook case for the One Health approach
Michel Bellaiche, Kimron Veterinary Institute, Israel
Title : Changing population immunity to COVID-19 in the context of infection, vaccination and emerging SARS-CoV-2 variants
Ranjan Ramasamy, IDFISH Technology, United States
Title : Candida auris infections are global health challenge
Reza Nassiri, Michigan State University, United States
Title : Host brakes on viral inflammation
Saurabh Chattopadhyay, University of Kentucky College of Medicine, United States